Keystone Dental Announces the Initiation of Five?year, Multi-Center Postmarket Clinical Study of Genesis Implant System to Evaluate Survival, Bone-level Changes, and Soft Tissue Aesthetics

Aug 22, 2011, 09:43 ET from Keystone Dental

BURLINGTON, Mass., Aug. 22, 2011 /PRNewswire/ -- Keystone Dental, an oral healthcare company focused on the delivery of breakthrough products to the oral healthcare space, announced today that a five-year, multi-center study to evaluate the long-term success of Genesis, The Biomimetic Implant System™, will begin this week. This postmarket surveillance study will evaluate both the long-term clinical and aesthetic success of the novel Genesis Implant System.

"We are thrilled to kick off this much anticipated study," said Pascal Girin, President and CEO of Keystone Dental, "especially given the caliber of clinicians participating in the study, including Dr. Dennis P. Tarnow as the lead investigator. We see this postmarket study as an example of the commitment we have made to delivering strong clinical evidence to the dental community."

The study will be conducted at eight centers within the United States with a total expected enrollment of approximately 120 patients. Genesis dental implants will be surgically placed and assessed at defined time points beginning one year post surgery. Additional safety and performance endpoints for the Genesis Implant System will be evaluated, including changes in bone height and soft tissue aesthetic outcomes.

"We know the design of the Genesis Implant System offers a number of significant advantages including an advanced surface, an aggressive thread design, and the first-ever marketed pink implant collar and abutment to improve aesthetic success," said Dr. Mariano Polack, DDS, MS, Prosthodontist, "and this study will demonstrate how it behaves long term, which is incredibly important information to the practicing clinician."

Keystone Dental is an oral healthcare company dedicated to the delivery of breakthrough technology. Keystone Dental's product portfolio includes Genesis, The Biomimetic Implant System™, The Prima™ Implant System, DynaMatrix® Extracellular Membrane, DynaBlast® and DynaGraft® bone graft substitutes, and Accell Connexus™, a next-generation bioactive bone grafting product. Founded in 2006, Keystone Dental's vision is to be a trusted oral healthcare partner focused on breakthrough technologies, whose goal is to inspire customers, instill pride in its employees, and deliver value every day.

SOURCE Keystone Dental